Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Identification of novel substrates for human cytochrome P450 2J2.

Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP 3rd, Freiwald S, Zientek M, Totah RA.

Drug Metab Dispos. 2010 Feb;38(2):347-56. doi: 10.1124/dmd.109.030270. Epub 2009 Nov 18.

2.

Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.

Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y.

Drug Metab Dispos. 2002 Nov;30(11):1240-5.

3.

Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.

Lee CA, Jones JP 3rd, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.

Drug Metab Dispos. 2012 May;40(5):943-51. doi: 10.1124/dmd.111.043505. Epub 2012 Feb 10.

4.

Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.

Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y.

J Pharmacol Exp Ther. 2002 Jan;300(1):298-304.

5.

Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.

Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M.

Drug Metab Dispos. 2012 Sep;40(9):1778-84. doi: 10.1124/dmd.112.045237. Epub 2012 Jun 11.

6.

Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner.

Lee E, Wu Z, Shon JC, Liu KH.

Drug Metab Dispos. 2015 Aug;43(8):1250-3. doi: 10.1124/dmd.115.064345. Epub 2015 Jun 5.

8.

Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.

Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH, Choi CS, Choi YK, Desta Z, Shin JG.

Drug Metab Dispos. 2006 Nov;34(11):1793-7. Epub 2006 Aug 8.

9.

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.

Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. Erratum in: Drug Metab Dispos. 2010 May;38(5):887. Frost, Charles A [corrected to Frost, Charles E].

10.

Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.

Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE.

Drug Metab Dispos. 2004 Dec;32(12):1434-45. Epub 2004 Sep 21.

11.
12.

Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.

Stringer RA, Strain-Damerell C, Nicklin P, Houston JB.

Drug Metab Dispos. 2009 May;37(5):1025-34. doi: 10.1124/dmd.108.024810. Epub 2009 Feb 5.

13.

Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells.

Andrews J, Abd-Ellah MF, Randolph NL, Kenworthy KE, Carlile DJ, Friedberg T, Houston JB.

Xenobiotica. 2002 Nov;32(11):937-47.

PMID:
12487724
14.

In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.

Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, Ducharme J.

Drug Metab Dispos. 2003 Jun;31(6):748-54.

15.
16.

Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.

Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S.

Drug Metab Pharmacokinet. 2011 Jun;26(3):300-6. doi: 10.2133/dmpk.DMPK-10-SH-119. Epub 2011 Mar 4.

17.

Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.

Ghosal A, Lu X, Penner N, Gao L, Ramanathan R, Chowdhury SK, Kishnani NS, Alton KB.

Drug Metab Dispos. 2011 Jan;39(1):30-8. doi: 10.1124/dmd.110.035493. Epub 2010 Oct 6.

18.
19.

In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam.

Tang J, Amin Usmani K, Hodgson E, Rose RL.

Chem Biol Interact. 2004 Apr 15;147(3):319-29.

PMID:
15135087
20.

Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.

Shou M, Lu T, Krausz KW, Sai Y, Yang T, Korzekwa KR, Gonzalez FJ, Gelboin HV.

Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.

PMID:
10771285

Supplemental Content

Support Center